Gabapentinoids are effective in a wide range of animal pain models and in patients with neuropathic pain and has become one of first-line treatments for neuropathic pain. Because spinal plasticity and sensitization have been intensely studied in neuropathic pain, most laboratory studies have focused on actions of gabapentinoids in the spinal cord, where they reduce primary afferent traffic and excitation of spinal nociceptive neurons, via interaction with α2δ subunits of voltage-gated Ca2+ channels. However, a recent clinical study questioned the relevance of this in vitro and in vivo rodent studies by demonstrating a complete lack of clinical efficacy of intrathecal gabapentin in patients with chronic pain. Curiously, preclinical studies continue to focus on spinal cord actions of gabapentinoids despite this lack of translation to humans.
We and others demonstrated that gabapentin inhibits presynaptic GABA release and induces glutamate release from astrocytes in the locus coeruleus (LC), thereby increasing LC neuron activity and spinal noradrenaline release, and that gabapentin relies on this action in the LC for its analgesia. We also recently discovered that, with prolonged time after neuropathic injury, noradrenergic neurons in the LC become less responsive to gabapentin, leading to impaired gabapentin analgesia, and that astroglial glutamate dysregulation is critical to this impaired LC response. The clinically available drug valproate increases glutamate transporter-1 (GLT-1) expression in the LC to restore this impaired gabapentin analgesia.
Neuropathic pain Gabapentin Locus coeruleus Astrocyte Glutamate transporter
This is a preview of subscription content, log in to check access.
This work was supported by grants DA27690 from the National Institutes of Health (Bethesda, Maryland, USA) and KAKENHI 16K08985 from the Japan Society for the Promotion of Science (Tokyo, Japan) to K. H.
Brawek B et al (2009) Effects of gabapentin and pregabalin on K+−evoked 3H-GABA and 3H-glutamate release from human neocortical synaptosomes. Naunyn Schmiedeberg’s Arch Pharmacol 379:361–369CrossRefGoogle Scholar
Gee NS et al (1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 271:5768–5776CrossRefPubMedCentralGoogle Scholar
Gotz E et al (1993) Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 43:636–638PubMedPubMedCentralGoogle Scholar
Harte M, O’Connor WT (2005) Evidence for a selective prefrontal cortical GABA(B) receptor-mediated inhibition of glutamate release in the ventral tegmental area: a dual probe microdialysis study in the awake rat. Neuroscience 130:215–222CrossRefPubMedCentralGoogle Scholar
Hayashida K et al (2007) Gabapentin activates spinal noradrenergic activity in rats and humans and reduces hypersensitivity after surgery. Anesthesiology 106:557–562CrossRefPubMedCentralGoogle Scholar
Kimura M, Eisenach JC, Hayashida K (2016) Gabapentin loses efficacy over time after nerve injury in rats: role of glutamate transporter-1 in the locus coeruleus. Pain 157:2024–2032CrossRefPubMedCentralGoogle Scholar
Kitamura R et al (2014) Gabapentin inhibits bortezomib-induced mechanical allodynia through supraspinal action in mice. J Pharmacol Sci 124:502–510CrossRefPubMedCentralGoogle Scholar
Luo ZD et al (2002) Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 303:1199–1205CrossRefPubMedCentralGoogle Scholar
Lynch JJ 3rd et al (2006) (L)-Phenylglycine, but not necessarily other alpha2delta subunit voltage-gated calcium channel ligands, attenuates neuropathic pain in rats. Pain 125:136–142CrossRefPubMedCentralGoogle Scholar
Miyazaki R, Yamamoto T (2012) The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model. Anesth Analg 115:182–188CrossRefPubMedCentralGoogle Scholar
Suto T et al (2014) Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms. Neuropharmacology 81:95–100CrossRefPubMedCentralGoogle Scholar
Takasu K, Ono H, Tanabe M (2008) Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. J Neurochem 105:933–942CrossRefPubMedCentralGoogle Scholar
Tanabe M et al (2005) Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharmacol 144:703–714CrossRefPubMedCentralGoogle Scholar
Yoshizumi M, Eisenach JC, Hayashida K (2012a) Riluzole and gabapentinoids activate glutamate transporters to facilitate glutamate-induced glutamate release from cultured astrocytes. Eur J Pharmacol 677:87–92CrossRefPubMedCentralGoogle Scholar
Yoshizumi M et al (2012b) Gabapentin inhibits gamma-amino butyric acid release in the locus coeruleus but not in the spinal dorsal horn after peripheral nerve injury in rats. Anesthesiology 116:1347–1353CrossRefPubMedCentralGoogle Scholar